Corpus ID: 8687340

Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.

@article{Giacoppo2015PurifiedCT,
  title={Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.},
  author={S. Giacoppo and T. Soundara Rajan and M. Galuppo and F. Pollastro and G. Grassi and P. Bramanti and E. Mazzon},
  journal={European review for medical and pharmacological sciences},
  year={2015},
  volume={19 24},
  pages={
          4906-19
        }
}
OBJECTIVE Multiple Sclerosis (MS) is a global concern disease leading to a progressive, chronic and demyelinating condition, affecting the central nervous system (CNS). The pathology has an inflammatory/autoimmune origin; nevertheless, neuronal cell death mechanisms are not to be underestimated. The present study was designed to test the effects of intraperitoneal administration of cannabidiol (CBD), the main non-psychotropic cannabinoid of Cannabis sativa (CS), in an experimental model of MS… Expand
The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroin fl ammatory diseases
Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressiveExpand
Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis.
TLDR
Results showed a clear downregulation of the PI3K/Akt/mTOR pathway following EAE induction and demonstrated that therapeutic efficacy of CBD treatment is due to reduction of pro-inflammatory cytokines, like IFN-γ and IL-17 together with an up-regulation of PPARγ. Expand
The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases
TLDR
Preclinical and clinical studies that could explain the therapeutic action of cannabinoid‐based medicines, as well as the medical potential of modulating endocannabinoid signaling in multiple sclerosis, with a link to other neuroinflammatory disorders that share common hallmarks and pathogenetic features are reviewed. Expand
Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload
TLDR
The reversal of iron-induced effects by CBD indicates that it has neuroprotective potential through its anti-apoptotic action, suggesting that iron can trigger cell death pathways by inducing intrinsic apoptotic proteins. Expand
Emerging potential of cannabidiol in reversing proteinopathies
TLDR
The potentiality of cannabidiol as a pharmacological modulator of the proteostasis network is discussed, highlighting its neuroprotective and aggregates clearing roles in the neurodegenerative disorders. Expand
Immune Responses Regulated by Cannabidiol
TLDR
Overall, the data overwhelmingly support the notion that CBD is immune suppressive and that the mechanisms involve direct suppression of activation of various immune cell types, induction of apoptosis, and promotion of regulatory cells, which, in turn, control other immune cell targets. Expand
Cannabidiol does not display drug abuse potential in mice behavior
TLDR
It is found that CBD lacks activity as a drug of abuse and should stimulate the development of the basic and clinical studies needed to elucidate its potential therapeutic use for the treatment of neuropsychiatric and drug use disorders. Expand
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
TLDR
Preclinical and clinical reports regarding the effects of CBD on the regulation of the reinforcing, motivational and withdrawal-related effects of different drugs of abuse such as alcohol, opioids (morphine, heroin), cannabinoids, nicotine, and psychostimulants are reviewed. Expand
Cannabidiol reverses memory impairments and activates components of the Akt/GSK3β pathway in an experimental model of estrogen depletion
Clinical and preclinical evidence has indicated that estrogen depletion leads to memory impairments and increases the susceptibility to neural damage. Here, we have sought to investigate the effectsExpand
Medical cannabis: Another piece in the mosaic of autoimmunity?
TLDR
In vitro and in vivo experiments in rheumatoid arthritis, diabetes type 1, and systemic sclerosis demonstrate a correlation between disease activity and cannabinoids, and several clinical trials suggest cannabis' effectiveness as an immune‐modulator. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 91 REFERENCES
Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice
TLDR
Cannabinoids, non-psychoactive CBs, attenuate neurobehavioral deficits, histological damage, and inflammatory cytokine expression in MOG-immunized animals, and there is an antagonistic interaction between CBD and PEA in protection against Mog-induced disease. Expand
A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis
TLDR
VCE-003 ameliorates the neurological defects and the severity of MOG-induced EAE in mice through CB2 and PPARγ receptor activation and dampened the IL-17-induced polarization of macrophages to a pro-inflammatory M1 profile. Expand
Cannabinoids and experimental models of multiple sclerosis.
TLDR
Continued studies of cannabinoid actions in EAE pathogenesis should be beneficial for the better understanding of the mechanisms governing such a vast array of physiological effects and in development of new therapeutic strategies for the treatment of human neuroinflammatory and neurodegenerative diseases. Expand
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids
TLDR
It is shown that synthetic cannabidiol can slow down the accumulation of disability from the inflammatory penumbra during relapsing experimental autoimmune encephalomyelitis (EAE) in ABH mice, possibly via blockade of voltage-gated sodium channels. Expand
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
TLDR
Using this viral model of multiple sclerosis (MS), it is demonstrated that CBD decreases the transmigration of blood leukocytes by downregulating the expression of vascular cell adhesion molecule-1, chemokines and the proinflammatory cytokine IL-1β, as well as by attenuating the activation of microglia. Expand
Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis
TLDR
The results suggest that JWH-133 acts at CB2 receptors, most likely within the dorsal horn of the spinal cord, to suppress the hypersensitivity associated with experimental autoimmune encephalomyelitis. Expand
Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
TLDR
Actively-induced EAE in mice is the easiest inducible model with robust and replicable results and is especially suited for investigating the effects of drugs or of particular genes by using transgenic mice challenged by autoimmune neuroinflammation. Expand
Cannabinoid control of neuroinflammation related to multiple sclerosis
TLDR
Cannabis may still affect the glial response within the damaged central nervous system, which facilitate the slow, neurodegenerative processes that account for progressive neurodegenersation, and therefore may have utility in addition to value of cannabis‐related drugs for symptom control. Expand
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.
TLDR
Data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA. Expand
Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases
TLDR
This review evaluates the most recent available data on cannabinoids utilization in experimental and clinical studies, and highlights their beneficial effects in the prevention of the main neurological diseases and for the clinical treatment of symptoms with them correlated. Expand
...
1
2
3
4
5
...